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PharmacokineticsAbstract Aims: To study the pharmacokinetics of selected drugs in plasma and saliva matrixes in
healthy human volunteers, and to suggest using non-invasive saliva sampling instead of plasma as a
surrogate in bioavailability and bioequivalence (BA/BE) studies.
Methods: Four different pilot BA/BE studies were done in 12–18 healthy humans. Saliva and
plasma samples were collected for 3–5 half life values of metformin, tolterodine, rosuvastatin,
and paracetamol after oral dosing. Saliva and plasma samples were assayed using LC-MSMS,
and then pharmacokinetic parameters were calculated by non-compartmental analysis using Kinet-
ica program. Effective intestinal permeability (Peff) values were also optimized to predict the actual
average plasma proﬁle of each drug by Nelder-Mead algorithm of the Parameter Estimation mod-
ule using SimCYP program.
Results: All studied drugs showed salivary excretion with strong correlation coefﬁcients between
saliva and plasma concentrations. The optimized Peff ranged 1.44–68.3  104 cm/s for the drugs
under investigation. Saliva/plasma concentrations ratios ranged 0.17–1.5. Inter and intra individual
variability of primary pharmacokinetic parameters in saliva matrix was either close to or higher
than plasma matrix. This requires larger sample size in saliva studies for some drugs.
Conclusion: Our results suggest that there is a potential in BA/BE studies for saliva to be consid-
ered as a surrogate for plasma concentration, which goes along with drug regulations. The use of
saliva instead of plasma in such studies makes them non-invasive, easy and with a lower clinical
burden.
 2016 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Salivary excretion of some drugs has been reported previously
as a good indicator for drug bioavailability, therapeutic drug
monitoring, pharmacokinetics and also drug abuse. Saliva
sampling offers simple, non-invasive and cheap method ass. Saudi
2 N.M. Idkaidekcompared with plasma sampling with no contamination risk
(Gorodischer and Koren, 1992; Ruiz et al., 2010). The rules
of drug protein binding and membrane permeability on sali-
vary excretion were previously investigated for several drugs,
where a Salivary Excretion Classiﬁcation System (SECS) was
proposed as shown in Table 1 (Idkaidek and Arafat, 2012).
High intestinal permeability corresponds to fraction absorp-
tion Fa > 0.9 and high protein binding corresponds to low
fraction unbound fu of <0.1 (Amidon et al., 1995; Sunil and
Philip, 2009). According to SECS classiﬁcation Class I drugs
of high intestinal permeability and low protein binding, such
as paracetamol, are subjected to salivary excretion. Class II
drugs of low permeability and low protein binding, such as
metformin, are subjected to salivary excretion since low perme-
ability is counterbalanced by low protein binding. Class III
drugs of high intestinal permeability and high protein binding,
such as tolterodine, are subjected to salivary excretion since
high protein binding is counterbalanced by high permeability.
Class IV drugs of low intestinal permeability and high protein
binding, such as montelukast, are not subjected to salivary
excretion (Idkaidek and Arafat, 2012).
Four pilot studies were previously done in our laboratory
on SECS class I drugs: paracetamol and tolterodine, SECS
class II drug: metformin and SECS class III drug: rosuvastatin.
Results were promising and have demonstrated high saliva-
plasma correlations with relatively higher variability in saliva
parameters (Idkaidek and Arafat, 2014a, 2014b, 2015, 2016).Table 1 Salivary Excretion Classiﬁcation System (SECS)
according to drug permeability (Peff) and fraction unbound to
plasma proteins (fu).
Class Parameter
Peﬀ fu Salivary excretion
Class I High High Yes
Class II Low High Yes
Class III High Low Yes
Class IV Low Low No
Figure 1 Paracetamol plasma and sa
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The objective of this review was to further investigate the
robustness of using non-invasive saliva sampling method
instead of plasma sampling method as a surrogate for bioavail-
ability and bioequivalence studies of SECS classes I, II and III
drugs that are excreted in saliva.
3. Experimental
Saliva BA/BE under fasted state, in 12–18 healthy human vol-
unteers after signing informed consent, was compared to
plasma pharmacokinetics in crossover or parallel design stud-
ies. Medical history, vital signs, physical examination, and lab-
oratory safety test results showed no evidence of clinically
signiﬁcant deviation from normal medical condition as evalu-
ated by the clinical investigator. The pilot bioavailability study
was conducted as per the ICH, GCP, and Helsinki declaration
guidelines after IRB of International Pharmaceutical Research
Center and Jordan FDA approvals. Single oral doses of study
drugs were administered after 10 h overnight fasting without
dietary restrictions. Then resting saliva (without stimulation)
and plasma samples were collected at speciﬁc time intervals
up to 3–5 half lives. Thorough rinsing of the mouth was done
after dosing to avoid contamination of saliva samples with any
drug residues. Sensitive and accurate LC-MS/MS methods
were developed and validated for the determination of study
drugs in human plasma and saliva (Idkaidek and Arafat,
2014a, 2014b, 2015, 2016).
4. Data analysis
4.1. Pharmacokinetic analysis
Individual pharmacokinetic parameters for drug concentration
in both saliva and plasma samples were calculated by non-
compartmental analysis (NCA) using Kinetica program V5.
Investigated pharmacokinetic parameters were area under
the concentration curves to last collection time (AUCt), maxi-
mum measured concentration (Cmax) and time to maximum
concentration (Tmax).liva mean proﬁles & correlations.
nd plasma for drug bioavailability and bioequivalence studies in humans. Saudi
Figure 2 Metformin plasma and saliva mean proﬁles & correlations.
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Figure 3 Tolterodine plasma and saliva mean proﬁles & correlations.
Figure 4 Rosuvastatin plasma and saliva mean proﬁles & correlations.
Saliva versus plasma bioavailability and bioequivalence in humans 34.2. Dimensional and correlation analysis
Saliva versus plasma concentration up to median Tmax value of
plasma data was correlated by linear regression using Micro-
soft Excel. On the other hand, dimensional analysis was done
on individual bases. This offers an advantage of more clearPlease cite this article in press as: Idkaidek, N.M. Comparative assessment of saliva a
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sionless ratios were calculated:
AUCt
* = saliva AUCt/plasma AUCt
Tmax
* = saliva Tmax/plasma Tmax
Cmax
* = saliva Cmax/plasma Cmaxnd plasma for drug bioavailability and bioequivalence studies in humans. Saudi
4 N.M. IdkaidekC* = saliva Concentration/plasma concentration = Cs/Cp
Peff
* = dimensionless effective permeability = (RPeff)/D
where D is drug diffusivity as predicted by SimCYP.
4.3. Absorption kinetics
Effective intestinal permeability (Peff) values were estimated by
Nelder-Mead algorithm of Parameter Estimation module
using SimCYP program (Jamei et al., 2009). Nelder-Mead
method, which is also called downhill simplex, is a commonly
used nonlinear optimization algorithm. This was done by
searching for the best parameter values that produce plasma
concentration that matches the actual plasma concentration
at the same time. The objective function is the weighted sum
of squared differences of observed and model predicted values.
Polar surface area (PSA) was used ﬁrst, using SimCYP, to pre-
dict initial estimate of Peff. Fraction absorption (Fa) was calcu-
lated according to equations below:
Fa = 1  e2An
An = Peff  tres/R
where An is the absorption number; R and tres are radius, set at
1.75 cm, and mean residence time, set at 3 h, in the human
small intestine respectively (Takamatsu et al., 2001).
5. Results and discussion
All reviewed drugs showed good salivary excretion with strong
correlation coefﬁcient between saliva and plasma concentra-
tions up to median Tmax values of plasma proﬁles as shown
in Figs. 1–4. Assuming one compartment linear model, sali-
vary excretion rate is dependent on plasma drug concentration.
This explains the close behavior of the saliva and plasma pro-
ﬁles. Dimensional analysis of all drugs under review is summa-
rized in Table 2. AUCt
* and Cmax
* values were in closeTable 2 Saliva/plasma dimensional analysis.
Parameter Tolterodine Paracetam
AUC* 0.42 1.36
Cmax
* 0.34 1.14
Tmax
* 2.37 1.47
C* 0.34 1.46
Peﬀ
* 248.39 1111.7
Table 3 BA/BE metrics and statistics in saliva matrix.
Tolterodinea Metform
AUCt 90%
C.I. (CV%)
1199 pgh/ml
(82)
61.8–12
(47.4)
Cmax 90%
C.I. (CV%)
338 pg/ml
(70)
64.1–10
(57.6)
Optimum N 55 66
a BA values represent calculated AUCt and Cmax with inter subject CV%
subject CV%.
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unity, AUCt
* and Cmax
* are also less than unity as in toltero-
dine, metformin and rosuvastatin. On the other hand such
parameters are more than unity in paracetamol.
However, Tmax
* values were more than unity, suggesting a
lag time between plasma and saliva compartments due to drug
distribution/redistribution processes in the body.
On the other hand, intra/inter subject variability values for
primary pharmacokinetic parameters in saliva matrix were
close to or more than plasma matrix as shown in Table 3
and Table 4. The optimum sample size, as calculated by Study
Result program V1, showed that more subjects are needed in
pivotal studies using saliva matrix as compared to plasma
matrix to demonstrate bioequivalence with adequate power
of more than 80%.
This explains why 90% conﬁdence intervals shown in
Table 3 and Table 4 did not fall within 80–125% acceptance
range, for all parameters with high variability values in such
pilot studies. Pilot studies are not meant to show bioequiva-
lence, but rather to compare saliva versus plasma matrices.
Pivotal studies are needed to be done in future to show bioe-
quivalence in both saliva and plasma matrices.
Mean concentration proﬁles of the reference product were
used to estimate the effective intestinal permeability values in
plasma and saliva. Fig. 3 shows observed versus SimCYP-
predicted concentration proﬁles with correlation coefﬁcients
of 0.88 indicating good ﬁtting of observed concentrations.
Optimized effective permeability coefﬁcients were
10.74  104 cm/s, with Fa = 1. This conﬁrms our previous
ﬁnding that effective permeability and protein binding are
major key factors in salivary excretion and our previous
assumption that intestinal permeability is similar to salivary
mucosal permeability (Idkaidek and Arafat, 2012).
From regulatory point of view, the US FDA guidance for
industry stated ‘‘The statutory deﬁnitions of BA and BE,
expressed in terms of rate and extent of absorption of the
active ingredient or moiety to the site of action, emphasizeol Metformin Rosuvastatin
0.27 0.17
0.38 0.35
1.29 1.47
0.39 0.18
21.79 890.7
in Paracetamol Rosuvastatin
6.6 85.2–120.3
(29.9)
57.7–115.9
(47.2)
9.8 78.3–135.1
(46.8)
61.3–124.8
(48.0)
48 50
. Optimum N was calculated assuming intra subject CV is half inter
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Table 4 BA/BE metrics and statistics in plasma matrix.
Tolterodinea Metformin Paracetamol Rosuvastatin
AUCt 90%
C.I. (CV%)
3152 pgh/ml
(77)
68.8–134.9
(48.6)
96.8–109.1
(10.2)
72.7–111.4
(28.8)
Cmax 90%
C.I. (CV%)
1237 pg/ml
(77)
69.8–125.1
(38.6)
86.8–116.5
(25.2)
76.3–151.6
(46.4)
Optimum N 48 54 24 48
a BA values represent calculated AUCt and Cmax with inter subject CV%. Optimum N was calculated assuming intra subject CV is half inter
subject CV%.
Saliva versus plasma bioavailability and bioequivalence in humans 5the use of pharmacokinetic measures in an accessible biologi-
cal matrix such as blood, plasma, and/or serum to indicate
release of the drug substance from the drug product into the
systemic circulation” (Food and Drug Administration, 2003).
Hence, from the data collected for drugs in SECS classes I,
II and III there is a high potential in BA/BE studies for saliva
to be considered as a surrogate for plasma concentration. This
line of research can help validate the newly proposed salivary
excretion classiﬁcation system. The use of saliva instead of
plasma in such studies makes them non-invasive, easy and with
lower clinical cost, less clinical staff and less clinical burden.
More research studies of candidate drugs that fall into
classes I, II and III will be done in order to compare saliva ver-
sus plasma bioavailability and bioequivalence; and demon-
strate SECS robustness.
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